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Abstract 
The aim of this study was to increase bioavailability of the antiviral drug acyclovir (ACV) when 
administered by the ocular route. For this purpose, a new lipophilic derivative of acyclovir was 
synthesized, both possessing greater lipophilicity and providing the formation of a homogeneous 
water dispersion with higher amount of ACV than the aqueous solution of the parent drug. This was 
done by chemically linking acyclovir to the isoprenoid chain of squalene, obtaining 
4′-trisnorsqualenoylacyclovir (SQACV), in which squalene is covalently coupled to the 4′-hydroxy 
group of acyclovir. This new prodrug was then formulated as nonpolymeric nanoassemblies through 
nanoprecipitation; the resulting particles were characterized in terms of mean diameter, zeta 
potential, and stability. The pharmacokinetic profile of the prodrug in the tear fluid and in the 
aqueous humor of rabbits was evaluated and compared to that of the parent drug. 
Data showed that SQACV nanoassemblies increased the amount of ACV in the aqueous humor of 
rabbits compared to free ACV solution. This new amphiphilic prodrug of acyclovir is a very promising 
tool to increase the ocular bioavailability of the parent drug. 
 
1. Introduction 
Topical administration of traditional ophthalmic formulations such as aqueous solutions and 
ointments is the preferred mode to treat ocular diseases that affect the anterior chamber of the eye, 
but, unfortunately, the ocular bioavailability of drugs administered in conventional formulations is 
very limited (2–10%). This is due to the small area available for drug penetration, the presence of 
absorption barriers, chiefly comprising the lipophilic corneal epithelium, and to the eye’s protective 
mechanisms [1] and [2]. Blinking, baseline, and reflex lachrimation and drainage reduce the contact 
time of the medication with the corneal surface [3], [4] and [5]. Repeated instillations induce the 
desired therapeutic effect but cause undesirable side effects, resulting from the systemic absorption 
through the nasolacrimal duct, estimated to absorb for more than 50% of the instilled 
dose [6] and [7]. 
During the last 2–3 decades, hydrogels, mucoahesive formulations, solid delivery devices (inserts, 
drug-soaked contact lenses), nano- and microparticulates, and/or chemical approaches to designing 
bioreversible prodrugs have been investigated, in the attempt to enhance the efficacy of ophthalmic 
medications, by prolonging the contact time between drug and ocular surface, or by increasing the 
affinity of the drug for corneal epithelium [8], [9], [10] and [11]. 
Acyclovir (9-(2-hydroxyethoxymethyl)guanine, ACV), a synthetic analog of 2′-deoxiguanosine, is one 
of the most effective and selective antiviral drugs. It is primarily used to treat ocular infections caused 
by Herpes simplex virus (HSV) (e.g. HSV epithelial keratitis), as well as in treating Varicella-zoster virus 
(VZV) infections (e.g. Herpes zoster ophthalmicus, HZO) [12], [13], [14], [15] and [16]. Acyclovir is 
commonly marketed as ophthalmic ointment (3%), because its poor water solubility does not enable 
the same concentration to be reached in eye drops. Moreover, its low lipophilicity limits acyclovir’s 
passage across the corneal epithelium and, consequently, its bioavailability. Different strategies have 
been used in order to improve the ocular bioavailability of acyclovir playing on either its water 
solubility or its lipophilicity to enhance transcorneal passage. In particular, it has been chemically 
modified to obtain water-soluble prodrugs [17], [18],[19], [20] and [21] or incorporated into several 
colloidal systems to enhance corneal adhesion; these include nanoparticles [22] and 
liposomes [23], [24] and [25]. However, it may be difficult to match high concentrations of acyclovir 
in water with the molecule’s increased lipophilicity that could promote drug transcorneal passage 
but limits its aqueous solubility. 
Recently, we conceived a new strategy to increase the therapeutic index of antitumoral and antiviral 
nucleoside analogs and to administer them more efficiently. This is achieved by coupling them to the 
acyclic isoprenoid chain of squalene, a precursor in sterol biosynthesis, whose conformation is 
strongly influenced by solvent polarity [26]. Coupling to the squalene moiety rendered the molecules 
amphiphilic, and able to spontaneously form spherical nanoassemblies dispersed in an aqueous 
medium [27], since in polar solvents squalene is tightly coiled [28] and [29]. In particular, this 
approach was applied to gemcitabine, obtaining 4-(N)-trisnorsqualenoylgemcitabine nanoassemblies 
with a higher anticancer activity than that of the parent drug [27]. 
In the present study, this experimental approach was applied to acyclovir, in order to obtain 
4′-trisnorsqualenoylacyclovir (SQACV). This new acyclovir derivative possesses both greater 
lipophilicity, due to the squalene tail, and increased water concentration, since it can be formulated 
as surfactant-free nonpolymeric nanoassemblies, through nanoprecipitation. Moreover, squalene 
has the added value to be a natural compound, both contained in the outermost oily layer of the tear 
film [30] and present as a structural component of the corneal epithelium [31]. 
This paper reports the synthesis of SQACV and the preparation and physicochemical characterization 
of the resulting nanoassemblies, in terms of mean particle size, polydispersity index, zeta potential 
and stability. Further, after quantitative analysis of SQACV entrapped within nanoassemblies, the 
pharmacokinetic behavior of SQACV nanoassemblies was studied in rabbits, measuring both the 
concentration of SQACV and of its regenerated parent drug (ACV) in tear fluid and aqueous humor. 
2. Materials and methods 
2.1. Materials and instruments 
1,1′,2-Trisnorsqualenoic acid was obtained from squalene as described elsewhere [32]. Acyclovir 
(purity ⩾99%) was purchased from Recordati (Milan, Italy), and dimethylaminopyridine and N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide were from Sigma (Milan, Italy). All other reagents and 
solvents used were of analytical grade from Carlo Erba Reagenti (Milan, Italy). The 1H nuclear 
magnetic resonance (NMR) spectra were recorded on a Bruker 300 Ultrashield instrument (Karlsruhe, 
Germany) in CDCl3 or DMSO at room temperature, with Me4Si (TMS) as internal standard. Mass 
spectra were obtained on a Finnigan-MAT TSQ 700 spectrometer (San Jose, CA). The reactions were 
monitored by thin-layer chromatography (TLC) on F254 silica gel pre-coated sheets (Merck, Milan, 
Italy); after development, the sheets were exposed to iodine vapor. Flash-column chromatography 
was performed on 230–400 mesh silica gel (Merck, Milan, Italy). All solvents were distilled prior to 
flash chromatography. 
 
2.2. Synthesis of 4′-trisnorsqualenoylacyclovir (SQACV) (9-[(4E,8E,12E,16E)-4,8,13,17,21-pentamethyl-
4,8,12,16,20-docosapentaenoyloxyethoxymethyl]-2-amino-1,7-dihydro-6H-purin-6-one) 
Dimethylaminopyridine (DMAP) (0.120 g, 0.980 mmol) in anhydrous N,N-dimethylformamide (DMF) 
(1.5 ml) was added, under nitrogen atmosphere and at room temperature, to a stirred solution of 
1,1′,2-trisnorsqualenoic acid (0.178 g, 0.444 mmol) in anhydrous DMF (1.5 ml). The mixture was then 
heated to 60 °C. A solution of acyclovir (0.100 g, 0.444 mmol) in anhydrous DMF (2.0 ml) was added 
dropwise to the stirred reaction mixture at the same temperature. N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC) (0.188 g, 0.980 mmol) in anhydrous DMF (1.5 ml) was then added. The 
reaction mixture was stirred for 3 days at 70 °C under nitrogen, and the formation of the desired 
product was monitored by TLC (ethanol/cyclohexane/chloroform 50:25:25) ( Fig. 1). The mixture was 
then evaporated in vacuo; the crude product was dissolved in dichloromethane, washed with HCl 3%, 
then with saturated brine until neutral pH, dried over anhydrous MgSO4, and concentrated under 
reduced pressure. The crude product was purified by silica gel flash chromatography, after eluting 
the column alone with dichloromethane/triethylamine, 99:1 and neutralizing with dichloromethane. 
The product was eluted with dichloromethane/ethanol 95:5. The ester was obtained as a light yellow 
waxy material; yield: 0.115 g, 42% [33]. 
 Fig. 1. - Reaction scheme for the synthesis of 4′-trisnorsqualenoylacyclovir. 
1H NMR (DMSO, 300 MHz) δ: 10.69 (broad s, 1 H, cycle 1-NHCO), 7.78 (s, 1 H, 8-CH), 6.57 (s, 2 H, NH2), 
5.32 (s, 2 H, 1′-NCH2O), 5.25–5.03 (m, 5 H, vinilyc CH), 4.06 (m, 2 H, 4′-CH2OCO), 3.63 (m, 2 H, 3′-
OCH2), 2.31 (t, 2 H, OCOCH2), 2.13 (t, 2 H, OCOCH2CH2), 2.10–1.94 (m, 16 H, allylic CH2), 1.65–1.52 
(m, 18 H, allylic CH3). 
Chemical ionization mass spectroscopy (CIMS; isobutane): m/z (%): 608 (100%). 
 
2.3. Preparation of nanoassemblies 
SQACV nanoassemblies (SQACV-N) were prepared by the nanoprecipitation technique[34]. 
Practically, SQACV was dissolved in acetone (10 mg/ml); this organic solution was then added 
dropwise under magnetic stirring into MilliQ® water (acetone/water 1:2 v/v). Precipitation of the 
nanoassemblies occurred spontaneously without using any surfactant. After solvent evaporation by 
Rotavapor®, an aqueous suspension of pure SQACV-N was obtained. The particle suspensions were 
then stored at 4 °C. 
 
 
 
2.4. Nanoassembly characterization 
The mean particle size and polydispersity index of SQACV-N were determined at 20 °C by Quasi-
elastic light scattering (QELS) using a nanosizer (Coulter® N4MD, Coulter Electronics, Inc., Hialeah, 
FL). The selected angle was 90°, and the measurement was taken after dilution of the nanoassembly 
suspensions in MilliQ® water. Each measure was carried out in triplicate. 
The stability of the nanosuspensions was evaluated by measuring the size of the particles after 
4 weeks of storage at 4 °C in MilliQ® water. The surface charge of SQACV-N was evaluated by zeta 
potential measurements after dilution of the suspensions in 10 mM KCl using a Zetasizer (Zeta 
Potential Analyzer Ver. 2.17, Brookhaven Inst. Corp., Holtsville, NY). The concentration of SQACV in 
the nanoassembly suspension was checked by HPLC (Merck Hitachi HPLC System, Milan, Italy): an 
aliquot of particle suspension was evaporated to dryness, dissolved in methanol containing 0.05% v/v 
trifluoroacetic acid (TFA) before HPLC analysis and then injected into a Symmetry C18 column, 5 μm 
(Merck, Milan, Italy) equipped with a C18 column guard (Merck, Milan, Italy). The column was eluted 
with methanol-TFA 0.05% (flow rate 1.0 ml/min). Detection was by UV absorption measurement at 
255 nm. Peak heights were recorded and processed on a CBM-10A Shimadzu interface. The drug 
concentration was calculated from a standard curve. The analytical method was validated, calculating 
linearity by regression analysis using the least squares method. The assay was linear (r2 = 0.9992) over 
the tested concentration range (20–1000 ng). 
 
2.5. Preparation of acyclovir formulations for biological studies 
An aqueous suspension of SQACV-N was prepared by diluting the pure SQACV dispersion with MilliQ® 
water to obtain a 0.48% w/w nanosuspension (equivalent to 0.18% w/w ACV) to use for biological 
studies. 
A reference aqueous solution of acyclovir (ACV-S) was prepared by dissolving the drug in phosphate 
buffer saline (PBS) to obtain an ACV concentration of 0.18% w/w. The osmolality of the preparation 
was adjusted to physiological values with sodium chloride, and pH was 6.5 [25]. 
 
2.6. Biological studies 
All experiments were performed in accordance with the ARVO Statement for the Use of Animal in 
Ophthalmic and Vision Research, following a protocol approved by the Ethical-Scientific Committee 
of the University of Pisa and under veterinary supervision. 
Male New Zealand albino rabbits weighing 2.8–3.5 kg, purchased from Pampaloni Rabbitry (Fauglia, 
Italy), were used throughout. They were housed in standard cages in a light-controlled room (10 h 
dark/14 h light cycle) at 19 ± 1 °C and 50 ± 5% relative humidity. They were fed a standard pellet diet 
and water ad libitum. During the experiments, the rabbits were placed in restraining boxes to which 
they had been habituated, in a room with dim lighting, and were allowed to move their heads and 
eyes freely. 
Different groups of rabbits, of six animals each, were used to determine (1) ACV retention time in the 
tear fluid and (2) ACV intraocular penetration studies. 
A single dose (2 × 50 μl, at 90 s intervals) [35] of either aqueous dispersion of nanoassemblies 
containing 0.48% w/w of SQACV or of ACV reference solution (ACV-S) containing 0.18% w/w of ACV 
was instilled into the lower conjunctival sac of one eye of each rabbit immediately after preparation. 
The amount of ACV administered was 0.18 mg in either case. 
For the precorneal acyclovir retention study, at appropriate time intervals (2, 5, 7, 10, 20, 30 and 
50 min) after administration of the formulations, 1.0 μl of tear fluid was collected using a microcaps 
(Drummond Scientific, Broomall, PA), and after appropriate dilution with HPLC mobile phase (1:100 
ratio), the samples were submitted to HPLC analysis in the conditions given above. 
The aqueous humor acyclovir levels were monitored at 30 and 60 min after instillation of the 
experimental formulations. Rabbit eyes were anesthetized with 50.0 μl of oxybuprocaine 
hydrochloride (Novesina® 0.5%, Novartis Farma S.p.A., Origgio, Italy), and 50.0 μl aqueous humor 
samples were collected using an insulin syringe (1.0 ml) fitted with a 29G needle (MicroFine, Becton 
Dickinson, Franklin Lakes, NJ). 
The aqueous humor samples were frozen immediately and stored at −18 °C. For analysis, thawed 
samples were mixed with an equal volume of HPLC mobile phase and centrifuged for 5 min at 
13,000 rpm (Microcentrifugette 4214, ALC International Srl, Milan, Italy), and 20 μl of the samples 
were submitted to HPLC analysis. 
The ocular tolerance and potential irritation of the experimental formulations, SQACV-N and ACV-S, 
were tested on at least three rabbits by instilling the same dose used in the pharmacokinetic protocol 
in one eye, while the other eye (reference) was treated with physiological saline. All the eyes were 
examined by slit-lamp 0.5, 1.0, 3.0 and 12 h after treatment, and the irritation was evaluated 
according to a scoring scale described in a previous paper [35]. 
 
2.7. HPLC analysis of biological samples 
Quantitative determination of ACV and SQACV in biological samples was carried out by HPLC. The 
apparatus consisted of a Shimadzu LC-20AD system with a SIL 10ADvp auto-injector, an UV SPD-10A 
detector and a computer integrating system. A LiChroCART® 250–4 (5 μm; RP-18 endcapped) column 
was employed. The mobile phase consisted of methanol-TFA 0.05% v/v. The detection wavelength 
was 255 nm, the flux was 1.0 ml/min, and the retention time was 3.70 and 9.54 min, for ACV and 
SQACV, respectively. 
ACV and SQACV standard curves were obtained by plotting the concentration of known solutions of 
ACV and SQACV vs the corresponding peak areas of HPLC chromatograms. Both stock solutions of 
ACV and SQACV and their dilutions were prepared in mobile phase. The analytical method was 
validated, calculating linearity by regression analysis using the least squares method and precision by 
injecting six times the standard solutions. 
The standard curves were obtained injecting eight standard solutions for ACV and SQACV and were 
linear (r2 = 0.9997–0.9996) in the detection range between 0.4345 μg/ml and 5.544 μg/ml, and 
between 1.820 μg/ml and 151.60 μg/ml, for ACV and SQACV, respectively [36]. The method was 
precise in the sample analysis: the coefficients of variation were of 1.33% and 3.32% at 0.80 and 
5.0 μg/ml and of 2.45% and 3.53% at 10.0 and 90 μg/ml, for six samples of ACV and SQACV, 
respectively. 
 
2.8. Statistical analysis and pharmacokinetic parameters 
Statistical differences between means were assessed by GraphPad Prism software (Prism 5, 
GraphPad software Inc., San Diego, CA), and the evaluation included calculation of means, standard 
errors, and group comparisons using the Student’s two-tailed unpaired t-test. Differences were 
considered statistically significant at p < 0.05. 
The area under the curve values (AUC) of SQACV and ACV concentration in tear fluid were calculated 
from the first observation (2 min after instillation, t2min) to the end of observation (50 min) from 
appropriate graphs, applying the linear trapezoidal rule (Prism 5, GraphPad software Inc., San Diego, 
CA). 
The apparent first-order elimination rate constants of SQACV and ACV from tear fluid (Ke) and the 
corresponding half-lives (t1/2) were calculated from the log-linear phase of drug concentration vs time 
profiles (Prism 5, GraphPad software Inc., San Diego, CA). 
3. Results 
3.1. Synthesis of 4′-trisnorsqualenoylacyclovir (SQACV) 
Pure 4′-trisnorsqualenoylacyclovir was obtained by the esterification of 1,1′,2-trisnorsqualenoic acid 
with acyclovir ( Fig. 1). The reaction was highly selective, with no formation of the amidic derivative 
of acyclovir, as checked by NMR and mass analysis: the signal at about 12 δ of the hypothetic amidic 
group was absent, while the 1H NMR spectrum showed the presence of free amino group at 6.57 δ 
(s, 2 H, NH2). Analysis of the 1H NMR spectra of the amide and ester acetyl derivatives of acyclovir 
reported in the literature confirmed the absence of the amide linkage between the squalene tail and 
acyclovir [37]. 
 
3.2. Preparation and characterization of nanoassemblies 
The SQACV prodrug was completely insoluble in water; it spontaneously self-organized into a 
nanoassembly suspension after dissolution in acetone and addition to water, according to the 
nanoprecipitation technique. 
By varying the drug concentration in the final nanoassembly suspension, preparations of SQACV 
nanoassemblies with different physicochemical characteristics could be obtained (Table 1). As found 
by QELS analysis, the SQACV nanoassemblies showed an uniform diameter with an unimodal size 
distribution (polydispersity index <0.1), ranging from about 100 to 250 nm, and a negative zeta 
potential in the range between −33.51 and −41.53 mV (Table 1). After 4 weeks of storage at 4 °C in 
water, no appreciable size change of nanoassemblies (<5% for all the nanosuspensions) was detected 
by QELS, and no precipitation or nanoassembly aggregation was observed. 
 
Table 1. - Characteristics of 4′-trisnorsqualenoylacyclovir (SQACV) nanoassemblies as a function of their final 
concentration after nanoprecipitation (means, n = 3). 
SQACV concentration in final suspension 
(mg/ml) 
Mean particle size 
(nm ± S.D.) 
Polydispersity 
index 
Zeta potential 
(mV ± S.D.) 
1 113 ± 41 0.077 −37.62 ± 4.50 
2 197 ± 38 0.087 −41.53 ± 1.98 
5 254 ± 52 0.042 −33.51 ± 2.99 
 
3.3. Biological studies 
The experimental formulations (SQACV-N and ACV-S) were perfectly tolerated: in no case, the 
relevant test evidenced symptoms of ocular irritation. 
The pharmacokinetic behavior of the two formulations (ACV-S and SQACV-N) in tear fluid is illustrated 
in Fig. 2, as individual profiles of the concentration of ACV and SQACVvs time, resulting from topical 
administration of ACV-S and SQACV-N formulations, respectively. The total amount of ACV in tear 
fluid (total-ACV) compared with the concentration of intact-ACV measured after the instillation of 
ACV-S is also illustrated inFig. 3. Total-ACV was calculated as sum of ACV produced by 
biotransformation of the SQACV conjugate (regenerated-ACV) and by transformation of the SQACV 
experimental data considering the MW of each compound (intact-SQACV). 
 
 
Fig. 2. - Tear fluid concentration vs time profiles of ACV and SQACV upon topical administration of (■) reference 
ACV aqueous solution (ACV-S) and (♢) SQACV nanoassemblies (SQACV-N) formulations, respectively. 
(Means ± S.E., n = 6). 
 Fig. 3. - Tear fluid concentration vs time profiles of ACV after administration of (▴) SQACV-N (total-ACV) and (■) 
ACV-S (intact-ACV) formulations. (Means ± S.E., n = 6, *: significantly different from ACV-S (p < 0.05)). 
Table 2 summarizes the precorneal pharmacokinetic parameters, as apparent first-order elimination 
rate constants from tear fluid (Ke), relevant half-lives (t1/2), concentrations measured at 2 min, AUC 
values of different species of ACV (regenerated-, intact- and total-ACV) after ocular administration of 
ACV-S and SQACV-N formulations. 
Table 2. - Pharmacokinetic parameters in tear fluid of rabbits (means ± S.E., n = 6). 
Formulations Compound C2min(×102 mg/ml) 
AUC 
(mg/ml min−1) Ke (×102 min−1) t1/2 (min) 
SQACV-N Intact-SQACV 434.70 ± 56.40⁎ 29.23 ± 5.46 7.46 ± 0.66⁎ 9.29 ± 0.97 
 Regenerated-
ACV 
5.99 ± 1.89⁎ 0.74 ± 0.16 3.89 ± 0.41⁎ 17.80 ± 1.37 
 Total-ACV 169.00 ± 21.00⁎ 11.78 ± 2.06 6.95 ± 1.03⁎ 9.97 ± 2.11 
ACV-S Intact-ACV 40.40 ± 9.10 2.97 ± 0.34 10.09 ± 0.40 6.87 ± 1.13 
⁎ Significantly different from ACV-S (p < 0.05). 
As shown in Figures and Tables, higher SQACV tear fluid levels were provided in rabbits by SQACV-N 
dispersion immediately after their administration (7.245 mM corresponding to 4.347 mg/ml at 2 min) 
and up to 20 min (0.345 mM corresponding to 0.207 mg/ml). Detectable drug levels were measured 
up to 50 min after instillation of the nanoassemblies, with a 0.00733 mM concentration of SQACV 
corresponding to 0.0044 mg/ml. The slow decrease in the SQACV concentration is evidenced by its 
elimination rate constant and by its half-life, respectively 0.0746 min−1 and 9.29 min. After 
administration, the SQACV-N dispersion undergoes hydrolysis, producing a reasonably constant 
amount of regenerated-ACV in the tear fluid, ranging from 0.0599 mg/ml 2 min after instillation to 
0.0027 mg/ml at the end of the pharmacokinetic analysis time. The slow elimination rate of 
regenerated-ACV from tear fluid is evidenced by Ke and t1/2f values of 0.0389 min−1 and 17.80 min, 
respectively. The chemical behavior of SQACV determines the presence of significantly higher tear 
fluid ACV levels with respect to reference ACV-S formulation from 2 min up to 10 min after instillation 
(p < 0.05, see Fig. 3). 
Conversely, after instillation of ACV-S solution, the concentration of intact-ACV decreased rapidly in 
the tear fluid, from 0.80 to 0.13 mM in less than 30 min (corresponding to 0.404 and 0.026 mg/ml, 
respectively), with a higher elimination rate constant (Ke = 0.1009 min−1 and t1/2 = 6.87 min), as 
expected for aqueous solution (ACV-S). The increased residence time of the prodrug in the tear fluid 
caused a substantial statistical reduction in the elimination of ACV from the tear fluid (Ke: total-
ACV = 6.95 min−1vs intact-ACV = 10.09 min−1). The data are clearly indicative of the greater ACV 
bioavailability produced by the SQACV-N dispersion being more than threefold that of the ACV-S 
reference solution (AUC = 11.783 and 2.969 mg/ml min−1 for SQACV-N and ACV-S, respectively). 
The concentrations of ACV in the aqueous humor of rabbits, 30 and 60 min after topical 
administration of the formulations under study, are reported in Table 3. 
 
Table 3. - Concentration of ACV in the aqueous humor of rabbits (means ± S.E., n = 6). 
Formulations 
ACV concentration (μg/ml) 
 
30 min 60 min 
SQACV-N 0.798 ± 0.206⁎ 0.294 ± 0.119 
ACV-S 0.126 ± 0.030 0.098 ± 0.051 
⁎ Significantly different from ACV-S (p < 0.05). 
 
While both intact-SQACV and regenerated-ACV were detected in the tear fluid, after administration 
of SQACV-N dispersion, only regenerated-ACV was detected in the aqueous humor: its concentration 
in the anterior chamber was about six- and threefold higher than that measured after instillation of 
ACV-S solution, at 30 and 60 min, respectively, even if statistically significant differences in the 
concentration were observed at 30 min exclusively. However, the lowest concentration of ACV 
detected in the aqueous humor after instillation of the SQACV-N formulation (corresponding to 
0.294 μg/ml of the parent drug) was higher than any of those obtained after administration of ACV-
S solution. 
 
4. Discussion 
This study investigated a combination of two different strategies, in the attempt to develop a 
promising ocular delivery system, suitable to enhance the therapeutic activity of acyclovir. We 
selected a prodrug that would increase the lipophilic character of acyclovir, optimizing its permeation 
through the cornea, and simultaneously the appropriate nanotechnology to provide prolonged 
release of acyclovir at the absorption site. Each of these approaches has been widely studied: 
macromolecular complex, amino acid ester, and dipeptide prodrugs of acyclovir were found to be 
more stable, more soluble, and capable of improving the bioavailability of ACV after oral and ocular 
administration [17], [19], [20], [21], [38] and [39], and colloidal carriers have been widely exploited 
to enhance corneal permeation, control drug release at the absorption site, and obtain a selective 
target of acyclovir [35], [40] and [41]. 
The rationale for using a prodrug is the presence of chemical and enzymatic processes that take place 
in the precorneal area and within the cornea. It is well known that esterases are present in several 
ocular structures, and their activity is the main factor responsible for the bioreversion of amino acid 
prodrugs of acyclovir [19], [39] and [42]. 
Our study employed a lipophilic prodrug of ACV, obtained by conjugation with 
1,1′,2-trisnorsqualenoic acid, as has been proposed by Sarpietro et al. [33] and [43]. In particular, 
Sarpietro et al. highlighted the fact that the formation of a lipophilic prodrug gives rise to a stronger 
interaction with the biomembrane model and is absorbed in larger quantities by the biomembrane 
model constituted by dimyristoylphosphatidylcholine, than 1,1′,2-trisnorsqualenoic 
acid [33] and [43]. The results reported by Sarpietro et al. using differential scanning calorimetry 
(DSC) analysis [33] indicated that 1,1′,2-trisnorsqualenoic acid and SQACV had a fluidizing effect on 
the phospholipid bilayer, interacting with the hydrophobic acyl chains, while acyclovir does not enter 
the phospholipid bilayers [44]. 
Moreover, squalene’s conformation is strongly influenced by solvent polarity, so that in polar solvents 
it is tightly coiled. This unique property is maintained in squalene-drug conjugates, such as SQACV, 
so that it is possible to obtain nanoassemblies from these derivatives in water without adding any 
surfactant. Squalene is also a structural constituent of the corneal epithelium, being a precursor of 
cholesterol, and in addition, it is a component of the lipid layer of the precorneal tear film, together 
with wax esters, cholesterol esters, triglycerides, diglycerides, monoglycerides, free fatty acids, free 
cholesterol, phospholipids, sterol esters, and polar lipids [31]. 
Herpetic keratitis, defined as the corneal infection caused by Herpes simplex virus type 1 (HSV-1), 
may be superficial when it affects only the corneal epithelial cells, or may affect the deeper layers of 
the cornea, causing a pathological condition known as stromal keratitis. ACV is utilized exclusively in 
superficial corneal keratitis, as a result of its poor corneal permeability and its limited paracellular 
diffusion. Enhancement of the residence time of ACV in the tear fluid, and/or of its penetration into 
the corneal structure to reach the aqueous humor, would thus appear a promising therapeutic goal 
that could be achieved using the SQACV prodrug. 
As demonstrated in this work, the ocular administration of SQACV prodrug increased the 
bioavailability of ACV in both the tear fluid and in the aqueous humor, as much as four- and sixfold 
the reference values, respectively. The intact prodrug was found in the lacrimal fluid, while it was not 
detected in the aqueous humor, thus ruling out passive transcorneal diffusion of the conjugate. 
Anyway, its lipophilic character associated with its high affinity for the ocular structure could improve 
the availability of ACV on the corneal surface, as highlighted also from the significant reduction in the 
elimination rate constant (Ke). 
All these considerations partially explain the high bioavailability of ACV after instillation of SQACV 
nanoassemblies. The longer residence time of SQACV in the precorneal area compared to ACV 
solution could be due to the technological characteristics of the formulation. 
Although several studies have reported data on the increase in ocular bioavailability after 
administration of positively charged colloidal formulations, due to interaction with the corneal 
epithelium, the presence of a negative charge, as in SQACV-N (mean zeta potential about −33 mV), 
does not seem to be a limiting factor [45] and [46]. Furthermore, it should be borne in mind that 
particulate systems with a size of 100–200 nm can be retained on the corneal surface, and also in the 
conjunctival sac, for longer times than can an aqueous solution of the drug, avoiding the loss via tear 
turnover, as demonstrated by the t1/2 value calculated for SQACV nanoassemblies 
(t1/2 = 9.29 min) [11]. 
The ACV EC50 value for HSV-1 in the aqueous humor is 7.1 μM [20], corresponding to a concentration 
of 1.6 μg/ml. Although the formulation SQACV-N determines an active concentration of ACV in the 
tear fluid, its concentration in the aqueous humor remains below the EC50 value. However, the good 
ocular tolerability of the nanoassemblies prompted us to hypothesize the possibility of increasing the 
instilled dose of SQACV-N, and thus the acyclovir level in the aqueous humor, making the formulation 
useful in the case of stromal keratitis. 
 
5. Conclusions 
The linkage between acyclovir and squalene afforded a new amphiphilic prodrug, SQACV, which 
forms nanoassemblies without surfactants. These nanoassemblies are more advantageous than the 
free nucleoside analog in solution, since they provide the formation of a homogeneous water 
dispersion with high amount of ACV and, at the same time, increase its ocular bioavailability. Studies 
are in progress to further characterize the nanoassemblies (e.g. with electron microscopy, TEM and 
SEM) and to improve the formulation in order to achieve adequate therapeutic activity. 
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